<DOC>
	<DOC>NCT00198978</DOC>
	<brief_summary>The study evaluates the efficacy and tolerability of a dose-reduced chemotherapy for the treatment of elderly patients with acute lymphoblastic leukemia. In patients with expression of CD20 on leukemic cells the efficacy and tolerability of additional application of Rituximab together with chemotherapy is evaluated.</brief_summary>
	<brief_title>German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Diagnosis of acute lymphoblastic leukemia (pro B, pre B, cALL or TALL), proved by morphology and immunophenotyping Age &gt; 55 yrs (no upper age limit) Written informed consent Severe leukemia associated complications, not controllable before therapy onset e.g. life threatening infections as sepsis, pneumonia, hypoxia, shock, life threatening bleeding) Severe comorbidity e.g. decompensated renal failure if not caused by leukemia with Creatinine &gt; 2x ULN heart failure (NYHA II/IV), instable Angina, significant coronary stenosis hepatic insufficiency e.g. liver cirrhosis or chronic active hepatitis with bilirubin &gt; 1,5 x ULN and/or ASA, ALA, AP &gt; 2,5 ULN decompensated metabolic disturbances (e.g. not controllable diabetes) severe obstructive or restrictive pulmonary disease with hypoxaemia Severe psychiatric illness or other circumstances which may compromise cooperation of the patient Active second neoplasia HIV infection Severely reduced general condition Cytostatic pretreatment of ALL Chemotherapy treatment of any other malignancy during the last 5 years Participation in other clinical trials interfering with the study therapy</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>ALL</keyword>
	<keyword>Treatment</keyword>
	<keyword>Elderly</keyword>
	<keyword>De novo</keyword>
</DOC>